Posted on 1 May 20251 May 2025 FDA approves J&J’s Imaavy for generalised myasthenia gravis Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has rec...
